Advertisement

Introduction to Cellular Drug Delivery

Present Realities and Future Prospects
  • Kinam Park
Chapter
  • 118 Downloads

Abstract

Drugs play a central role in modern medicine (1). The total global pharmaceutical market in 2002 was more than $400 billion, and the annual growth rate of the global market has been more than 10%. The large market size allows big pharmaceutical companies to invest heavily in research and development (R&D). In 2002 alone, the combined R&D budget of Pfizer, Pharmacia, Merck, Eli Lilly, and Bristol-Myers Squibb was more than $16 billion. Despite an ever-increasing R&D budget, development of new drugs has been slow, and the number of new drugs introduced has become smaller than the number of drugs that went off patent protection. The real cost of developing a new drug is not well established, but it is generally agreed to be about $800 million. One of the reasons for such a high cost is that many drug candidates are abandoned owing to their unfavorable physicochemical and biochemical properties. It is also becoming more and more difficult to develop new drugs due to the increasing difficulty of reaching their intended targets. One of the ways of making drug development more efficient is to utilize drug-delivery technologies from the early stages onward. The development of new drug-delivery technologies also makes the existing drug more useful.

Keywords

Ethylene Oxide Severe Acute Respiratory Syndrome Polymeric Micelle Severe Acute Respiratory Syndrome Nonviral Vector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Drews J. In Quest of Tomorrow’s Medicines. New York, NY, Springer-Verlag, 1999.Google Scholar
  2. 2.
    Langel Ü. Cell-Penetrating Peptides. Processes and Applications. Boca Raton, FL, CRC Press, 2002.Google Scholar
  3. 3.
    Nielsen PE. Peptide Nucleic Acids. Methods and Protocols. Totowa, NJ, Humana Press, 2002.CrossRefGoogle Scholar
  4. 4.
    Batrakova EV, Li S, Alakhov VY, et al. Optimal structure requirements for Pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 2003; 304: 845–854.PubMedCrossRefGoogle Scholar
  5. 5.
    Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 2003; 300: 615–618.PubMedCrossRefGoogle Scholar
  6. 6.
    Wagner E, Curiel D, Cotten M. Delivery of drugs, proteins and genes into cells using transfer-rin as a ligand for receptor-mediated endocytosis. Adv Drug Del Rev 1994; 14: 113–135.CrossRefGoogle Scholar
  7. 7.
    Plank C, Zauner W, Wagner E. Application of membrane-active peptides for drug and gene delivery across cellular membranes. Adv Drug Del Rev 1998; 34: 21–35.CrossRefGoogle Scholar
  8. 8.
    Midoux P, Monsigny M. Efficent gene transfer by histidylated polylysine/pDNA complexes. Biconjug Chem 1999; 10: 406–411.CrossRefGoogle Scholar
  9. 9.
    Putnam D, Gentry CA, Pack DW, Langer R. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci USA 2001; 98: 1200–1205.PubMedCrossRefGoogle Scholar
  10. 10.
    Benns JM, Choi JS, Mahato RI, pH-sensitive cationic polymer gene delivery vehicle: NAc-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer. Bioconjug Chem 2000; 11: 637–645.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Kinam Park

There are no affiliations available

Personalised recommendations